Tobramycin - NDC Database (Page 6)
70644-899 Jul 11, 2016
Tobramycin Inhalation Solution Pak 300 mg/5ml Respiratory (Inhalation) Solution by Genericus, Inc.
Tobramycin Inhalation Solution Pak 300 mg/5ml Respiratory (Inhalation) Solution by Genericus, Inc.
70700-173 Jul 12, 2021
Tobramycin 1.2 g/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Xiromed LLC
Tobramycin 1.2 g/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Xiromed LLC
70756-604 Jun 30, 2023
Tobramycin 300 mg/5ml Respiratory (Inhalation) Solution by Lifestar Pharma LLC
Tobramycin 300 mg/5ml Respiratory (Inhalation) Solution by Lifestar Pharma LLC
70756-617 Sep 23, 2022
Tobramycin 300 mg/4ml Respiratory (Inhalation) Solution by Lifestar Pharma LLC
Tobramycin 300 mg/4ml Respiratory (Inhalation) Solution by Lifestar Pharma LLC
72266-163 Aug 11, 2021
Tobramycin 1.2 g/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Fosun Pharma USA Inc
Tobramycin 1.2 g/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Fosun Pharma USA Inc
72603-160 Apr 01, 2024
Tobramycin 1.2 g/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Northstar Rx LLC
Tobramycin 1.2 g/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Northstar Rx LLC
76204-029 Mar 25, 2025
Tobramycin 300 mg/5ml Respiratory (Inhalation) Solution by Ritedose Pharmaceuticals, LLC
Tobramycin 300 mg/5ml Respiratory (Inhalation) Solution by Ritedose Pharmaceuticals, LLC
80425-0341 May 24, 2023
Tobramycin 3 mg/ml Ophthalmic Solution by Advanced Rx Pharmacy of Tennessee, LLC
Tobramycin 3 mg/ml Ophthalmic Solution by Advanced Rx Pharmacy of Tennessee, LLC
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.